PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 69 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $115,013,399 | +5.8% | 3,319,290 | -11.6% | 3.22% | +7.9% |
Q1 2024 | $108,660,791 | -17.5% | 3,755,990 | -34.6% | 2.99% | -9.4% |
Q4 2023 | $131,729,365 | +37.5% | 5,744,848 | 0.0% | 3.30% | +27.6% |
Q3 2023 | $95,824,065 | -8.1% | 5,744,848 | +52.1% | 2.58% | -11.1% |
Q2 2023 | $104,290,358 | +20.1% | 3,775,900 | 0.0% | 2.91% | -8.4% |
Q1 2023 | $86,845,700 | +892.0% | 3,775,900 | +241.1% | 3.18% | +650.6% |
Q2 2022 | $8,755,000 | -91.2% | 1,106,838 | -73.5% | 0.42% | -89.3% |
Q1 2022 | $99,059,000 | -20.7% | 4,183,219 | +14.6% | 3.96% | -12.6% |
Q4 2021 | $124,890,000 | +80.6% | 3,651,759 | -6.4% | 4.53% | +68.1% |
Q3 2021 | $69,139,000 | -59.0% | 3,901,759 | +3.9% | 2.70% | -57.3% |
Q2 2021 | $168,484,000 | +64.3% | 3,754,095 | -5.2% | 6.32% | +64.2% |
Q1 2021 | $102,550,000 | +19.0% | 3,959,451 | -7.4% | 3.84% | +13.5% |
Q4 2020 | $86,156,000 | +85.8% | 4,273,588 | +80.1% | 3.39% | +34.2% |
Q3 2020 | $46,378,000 | +10.9% | 2,372,288 | +0.2% | 2.53% | -2.0% |
Q2 2020 | $41,806,000 | +755.1% | 2,367,288 | +241.9% | 2.58% | +465.4% |
Q1 2020 | $4,889,000 | +1.6% | 692,430 | +1.4% | 0.46% | +24.9% |
Q4 2019 | $4,813,000 | -41.3% | 682,630 | 0.0% | 0.36% | -57.6% |
Q3 2019 | $8,198,000 | -36.4% | 682,630 | -35.8% | 0.86% | -38.8% |
Q2 2019 | $12,883,000 | -8.8% | 1,063,802 | -5.3% | 1.41% | -11.0% |
Q1 2019 | $14,119,000 | +28.0% | 1,123,255 | -31.5% | 1.58% | +9.6% |
Q4 2018 | $11,034,000 | -59.0% | 1,639,458 | -37.4% | 1.44% | -39.1% |
Q3 2018 | $26,939,000 | +182.7% | 2,617,967 | +84.6% | 2.37% | +154.5% |
Q2 2018 | $9,529,000 | +173.5% | 1,417,967 | +249.6% | 0.93% | +163.5% |
Q1 2018 | $3,484,000 | -43.1% | 405,600 | +37.9% | 0.35% | -52.2% |
Q4 2017 | $6,118,000 | -22.8% | 294,117 | -21.6% | 0.74% | -50.6% |
Q3 2016 | $7,924,000 | – | 375,000 | – | 1.49% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |